Real-world safety and effectiveness of lurasidone in Chinese children and adolescents with schizophrenia: Findings from a prospective cohort

Table 1 Baseline characteristics of pediatric and adult patients receiving lurasidone monotherapy, mean ± SD/n (%)

Outcome measures	Pediatric (n = 140)	Adult (n = 1332)	P value
Male	51 (36.4)	598 (44.9)
Age, year	15.4 ± 1.66	35.3 ± 13.29	< 0.001
BMI, kg/m2	21.8 ± 3.58	23.3 ± 3.58	< 0.001
Duration of illness, year	0.8 ± 0.97	6.1 ± 8.08	< 0.0011
Number of episodes	1.4 ± 0.81	3.1 ± 3.58	< 0.0011
Number of psychosis-related hospitalizations	0.6 ± 0.84	2.3 ± 3.80	< 0.0011
Number with comorbid mental disorders		5 (0.4)
Number with family history of mental disorders	20 (14.3)	107 (8.0)	0.0122
BPRS
Total score-baseline	45.6 ± 15.67	43.9 ± 16.50
Anxiety-depression	10.8 ± 4.15	9.6 ± 4.30	0.001
Negative symptoms	8.3 ± 3.54	8.7 ± 3.72
Positive symptoms	10.8 ± 4.28	10.7 ± 4.58
Activation	6.3 ± 3.08	6.0 ± 3.14
Hostility-suspiciousness	9.3 ± 3.96	8.9 ± 3.97
ICD-11 symptom rating scale
Positive symptoms	2.3 ± 0.93	1.8 ± 0.88	0.001
Negative symptoms	1.4 ± 0.81	1.3 ± 0.75
Depressive mood symptoms	1.5 ± 0.91	1.0 ± 0.77	< 0.001
Manic mood symptoms	0.7 ± 0.85	0.7 ± 0.74
Psychomotor symptoms	1.2 ± 0.91	0.9 ± 0.80
Cognitive symptoms	1.7 ± 0.97	1.2 ± 0.79	< 0.001

¹P values calculated from Welch’s t-test.

²P values calculated from χ² test.

P values are derived from two-sample equal variance t-tests unless otherwise indicated. BMI: Body mass index; BPRS: Brief Psychiatric Rating Scale; ICD-11: International Classification of Diseases 11th Revision.